Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma

Virchows Archiv

Volumn 462, Issue 1, 2013, Pages 73-81

  Ye, Jin ^a   Liu, Hui ^a   Hu, Yanming ^b   Li, Peng ^a   Zhang, Gehua ^a   Li, Yuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Indoleamine 2,3 dioxygenase; Prognostic factor; Regulatory T lymphocytes; Squamous cell carcinomas; Tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DENSITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHINA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LARYNGEAL NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872303786     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1340-x     Document Type: Article

References (36)

1. Mellor AL, Chandler P, Lee GK et al (2002) Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J Reprod Immunol 57:143-150
2. Godin-Ethier J, Hanafi LA, Piccirillo CA et al (2011) Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17:6985-6991
3. Prendergast GC, Chang MY, Mandik-Nayak L et al (2011) Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 18:2257-2262
4. Johnson BA 3rd, Baban B, Mellor AL (2009) Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy 1:645-661
5. Uyttenhove C, Pilotte L, Théate I et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269-1274
6. Funeshima N, Fujino M, Kitazawa Y et al (2005) Inhibition of allogeneic T-cell responses by dendritic cells expressing transduced indoleamine 2,3-dioxygenase. J Gene Med 7:565-575
7. Sørensen RB, Køllgaard T, Andersen RS et al (2011) Spontaneous cytotoxic T-cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res 71:2038-2044
8. Mellor AL, Keskin DB, Johnson T et al (2002) Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 168:3771-3776
9. Liu X, Newton RC, Friedman SM et al (2009) Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets 9:938-952
10. Allen CT, Judd NP, Bui JD et al (2012) The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 122:144-157
11. Pan K, Wang H, Chen MS et al (2008) Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 134:1247-1253
12. Riesenberg R, Weiler C, Spring O et al (2007) Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 13:6993-7002
13. Brandacher G, Perathoner A, Ladurner R et al (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12:1144-1151
14. Okamoto A, Nikaido T, Ochiai K et al (2005) Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11:6030-6039
15. Liu H, Zhang T, Li X et al (2008) Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci 99:2185-2192
16. Engin AB, Ozkan Y, Fuchs D et al (2010) Increased tryptophan degradation in patients with bronchus carcinoma. Eur J Cancer Care (Engl) 19:803-808
17. Suzuki Y, Suda T, Furuhashi K et al (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67:361-365
18. Yu J, Sun J, Wang SE et al (2011) Upregulated expression of indoleamine 2,3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol. doi: 10.1155/2011/469135
19. Laimer K, Troester B, Kloss F et al (2011) Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 47(5):352-357
20. Liu J, Lu G, Tang F et al (2009) Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas. Virchows Arch 455:441-448
21. Zhang G, Liu WL, Zhang L et al (2011) Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma. Clin Dev Immunol. doi: 10.1155/2011/384726
22. Elkord E, Alcantar-Orozco EM, Dovedi SJ et al (2010) T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 10:1573-1586
23. Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203-213
24. Vesalainen S, Lipponen P, Talja M et al (1994) Histological grade, perineural infiltration, tumourinfiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 30:1797-1803
25. Ropponen KM, EskelinenMJ LPK et al (1997) Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182:318-324
26. Ino K, Yamamoto E, Shibata K et al (2008) Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14:2310-2317
27. Rudensky AY (2011) Regulatory T cells and Foxp3. Immunol Rev 241:260-268
28. Fallarino F, Grohmann U (2011) Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. Curr Med Chem 18:2215-2221
29. Sun J, Yu J, Li H et al (2011) Upregulated expression of indoleamine 2,3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells. J Exp Clin Cancer Res. doi: 10.1186/1756-9966-30-82
30. Munn DH (2011) Indoleamine 2,3-dioxygenase. Tregs and cancer. Curr Med Chem 18:2240-2246
31. Nakamura T, Shima T, Saeki A et al (2007) Expression of indoleamine 2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 98(6):874-881
32. Chen W, Liang X, Peterson AJ et al (2008) The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 181:5396-5404
33. Katz JB, Muller AJ, Prendergast GC (2008) Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 222:206-221
34. Silver CE, Beitler JJ, Shaha AR et al (2009) Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 266:1333-1352
35. Mendenhall WM, Mancuso AA, Hinerman RW et al (2007) Multidisciplinary management of laryngeal carcinoma. Int J Radiat Oncol Biol Phys 69:S12-S14
36. Marioni G, Marchese-Ragona R, Cartei G et al (2006) Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 32:504-515